knowledge -WSS

knowledge

author：fashion 2025-09-03 09:20:50 - browse：25199

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： FTC falls short on scrutinizing hospital mergers, study says

hotspot

WSS

Dogs on Prozac: What pet anti

Element Biosciences CEO lays out genome sequencing strategy

Emergent cuts jobs, executive role in business shake

Police still searching for prisoner who escaped from NYC hospital

How to use technology to prevent future drug shortages

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

explore

knowledge

explore

Malaria cases in Florida and Texas: Here’s what you need to know

After traumatic brain injury, life support decisions can use more time

Wildfire smoke exposes gaps in outdoor worker protections

Cancer researcher Catriona Jamieson is sending tumors into space

Anesthesiologist group: stop taking Ozempic before surgery

Naloxone nonprofit donates 200,000 doses after FDA approval

Wildfire smoke exposes gaps in outdoor worker protections

Close Medicare's dangerous gaps in addiction treatment coverage

Hollywood unions extend contract negotiations for actors

Exact Sciences stock tumbles despite strong cancer detection sales

leisure time

FTC falls short on scrutinizing hospital mergers, study says

Wegovy trial has doctors encouraged over new possibilities

Diversity in clinical trials starts with building trust, experts say

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The best solution to the drug shortages problem

Wegovy’s successful heart trial raises vital question about weight loss

focus

explore

hotspot

explore